SCA
KPTI icon

SAC Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

SAC Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-642
Closed -$221K – 1873
2013
Q4 		$221K Buy
+642
New +$177K ﹤0.01% 1588

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAC Capital Advisors's KPTI Position: Q1 2014 in Review

SAC Capital Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2014, closing a stake of 642 shares — an estimated $221K sold.

SAC Capital Advisors first reported a position in KPTI in Q4 2013 and held it in 1 quarter. The position peaked at $221K in Q4 2013. 60 funds tracked by Wall St. Rank hold KPTI as of Q1 2014.

  • SAC Capital Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 642 Karyopharm Therapeutics shares in Q1 2014, an estimated $221K.
  • SAC Capital Advisors first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 1 quarter.
  • SAC Capital Advisors's Karyopharm Therapeutics position peaked at $221K in Q4 2013.
  • 60 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2014.

Based on SAC Capital Advisors's 13F filing for Q1 2014, filed 15 May 2014.